Netflix beats expectations and reports stellar growth and forecasts for 2025. China could see 10% tariffs on goods going to the US from next month, which is lower than expected. UK public borrowing figures for Dec likely to weigh on bond market, and put pressure on UK to cut public spending quickly and rapidly.

Nasdaq 100 climbs at the opening bell as Netflix’s stellar earnings and AI investments fuel tech stock momentum. Will the rally sustain?

Donald Trump’s threat of a 10% tariff on goods imported from China today led to weaker sessions for the Shanghai Composite and the Hang Seng index. The benchmarks have fallen 0.9% and 1.8% respectively, while the Nikkei 225 is up by 1.6% after last night’s positive Wall Street session.

President Donald Trump's boost to AI demand hopes is outweighing fresh tariff threats on China and the EU, as earnings season rolls on.

Futures show both shares will keep on rising when markets open later on. Netflix is also on the up after reporting solid numbers, you can read the full Netflix report here, as part of our US company results coverage.

IMAX will partner with Netflix to release Greta Gerwig's 'Chronicles of Narnia' film adaptation on 1,000 screens for a month. Here's why.

Dow Jones futures were little changed while S&P 500 futures and Nasdaq futures rose slightly. Netflix surged late on strong earnings while United Airlines and Interactive Brokers rose on results.Late Tuesday,

President Donald Trump addresses relationship with China and Russia at World Economic forum in Davos.

FILE PHOTO: A trader works at the New York Stock Exchange (NYSE) next to a U.S. flag, after Republican Donald Trump won the U.S. presidential election, in New York City, U.S., November 6, 2024. REUTERS/Andrew Kelly/File Photo

Asian shares were mixed on Thursday after China rolled out more moves to try to boost its lagging stock markets by raising confidence that prices will rise. Officials in Beijing

Hong Kong shareholders of Shanghai Henlius Biotech on Wednesday rejected Chinese conglomerate Fosun International's buyout offer, which would have valued the drugmaker at HK$13.37 billion ($1.72 billion).